BridgeBio Pharma (BBIO) Debt Ratio (2018 - 2026)

BridgeBio Pharma has disclosed Debt Ratio across 9 years of filings, most recently posting 0.94 for Q1 2026.

• Debt Ratio for Q1 2026 came in at 0.94, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was 0.94 (changed N/A YoY), and the FY2025 annual result was 0.6, up 1.71% from the prior year.
• Debt Ratio came in at 0.94 for Q1 2026 at BridgeBio Pharma, up from 0.6 in the prior quarter.
• In the past five years, Debt Ratio ranged from a high of 0.94 in Q1 2026 to a low of 0.49 in Q2 2022.
• The 5-year median for Debt Ratio is 0.66 (2024), against an average of 0.66.
• Across the five-year window, Debt Ratio soared 518.25% in 2022 and plunged 37.32% in 2024, its largest moves.
• BridgeBio Pharma's Debt Ratio stood at 0.69 in 2022, then climbed by 18.12% to 0.82 in 2023, then declined by 27.43% to 0.59 in 2024, then gained by 1.71% to 0.6 in 2025, then jumped by 55.87% to 0.94 in 2026.
• The last three Debt Ratio figures came in at 0.94 (Q1 2026), 0.6 (Q4 2025), and 0.74 (Q3 2025), per Business Quant data.